Pay in 4 interest-free payments of $5.94 Learn more
Ships within 48 hours · Estimated delivery Aug 8 - Aug 13
Cross-Indication Pricing Implications With GLP-1 therapies spanning multiple indications, cross-indication pricing poses a strategic challenge
Without targeted policy interventions, such as expanded insurance coverage or income-based subsidy programs, the benefits of GLP-1 medications may continue to accrue disproportionately to higher-income populations, leaving behind the very communities most affected by obesity
An FDA decision is anticipated by late 2026
10.1038/nn.4540 69 TurtonM
What does the evaluation process involve
FDA Drug Approvals (2022) 9
US$ 24.73
US$ 25.59
US$ 21.36
